Skip to content

Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling #55

Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling

Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling #55

Triggered via issue July 6, 2026 14:33
Status Success
Total duration 21s
Artifacts
Fit to window
Zoom out
Zoom in

Annotations

1 notice
Journal publications table
Year|Title|URL|Source|DOI -|-|-|-|- 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/772">Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42321962/">https://pubmed.ncbi.nlm.nih.gov/42321962/</a>|CPT Pharmacometrics Syst Pharmacol. 2026 Jul;15(7):e70289.|<a href="https://doi.org/10.1002/psp4.70289">10.1002/psp4.70289</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/771">Physiologically Based Pharmacokinetic Modeling and Therapeutic Drug Monitoring for Ertapenem Dose Optimization in Hypoalbuminemia Elderly Patients</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42333386/">https://pubmed.ncbi.nlm.nih.gov/42333386/</a>|Drug Des Devel Ther. 2026 Jun 16:20:611549.|<a href="https://doi.org/10.2147/DDDT.S611549">10.2147/DDDT.S611549</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/770">An open-source framework for physiologically-based pharmacokinetic modeling of kinetics in the female reproductive tract</a>|<a href="https://doi.org/10.3389/fphar.2026.1797636">https://doi.org/10.3389/fphar.2026.1797636</a>|Front. Pharmacol. 17:1797636.|<a href="https://doi.org/10.3389/fphar.2026.1797636">10.3389/fphar.2026.1797636</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/769">Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42400597/">https://pubmed.ncbi.nlm.nih.gov/42400597/</a>|CPT Pharmacometrics Syst Pharmacol. 2026 Jul;15(7):e70295.|<a href="https://doi.org/10.1002/psp4.70295">10.1002/psp4.70295</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/768">Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42348273/">https://pubmed.ncbi.nlm.nih.gov/42348273/</a>|CPT Pharmacometrics Syst Pharmacol. 2026 Jul;15(7):e70292.|<a href="https://doi.org/10.1002/psp4.70292">10.1002/psp4.70292</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/767">Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41788629/">https://pubmed.ncbi.nlm.nih.gov/41788629/</a>|Front Mol Biosci. 2026 Feb 18:13:1768402.|<a href="https://doi.org/10.3389/fmolb.2026.1768402">10.3389/fmolb.2026.1768402</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/766">Dose Recommendation of Remimazolam Tosilate for General Anesthesia in Children and Adolescents: Synergistic Combination of PopPK and PBPK Approaches</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/41900801/">https://pubmed.ncbi.nlm.nih.gov/41900801/</a>|Pharmaceutics. 2026 Mar 1;18(3):315.|<a href="https://doi.org/10.3390/pharmaceutics18030315">10.3390/pharmaceutics18030315</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/765">Perfluorooctane sulfonate (PFOS) in follicular fluid and human granulosa cell dysfunction: a physiologically based toxicokinetic model translation of long-term low-level in vitro exposure data</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/42046577/">https://pubmed.ncbi.nlm.nih.gov/42046577/</a>|Hum Reprod Open. 2026 Apr 7;2026(2):hoag029.|<a href="https://doi.org/10.1093/hropen/hoag029">10.1093/hropen/hoag029</a> 2026|<a href="https://github.com/Open-Systems-Pharmacology/OSP-based-publications-and-content/issues/764">Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)</a>|<a href="https://pubmed.ncbi.nlm.nih.gov/40284407/">https://pubm